Updated August 2026
GHK-Cu Topical Powder Dosage: Concentration Math, Evidence, and Research Protocol
Research note: GHK-Cu topical powder is a formulation ingredient, not a finished serum, cream, or injectable. Label % may describe pure complex, peptide content, copper content, or a diluted carrier blend — not interchangeable. Powder calculations require assay correction. Historical 2%/4% wound gels cannot be converted directly into cosmetic facial protocols.
Human topical dosing is formulation-specific. The best-reported wound trial used 2% and 4% GHK-Cu gels once daily, metered by ulcer area (2 or 6 mg/cm²). NCT07437586 uses 0.1% gel × 14 days on paired punch wounds — twentyfold lower than the historical wound arms.
Cosmetic facial studies are often summarized as positive, but many accessible reports do not disclose active concentration, delivered mass, vehicle, or assay basis. Commercial “1% copper peptide” is frequently ambiguous — only 1% pure GHK-Cu w/w means 10 mg active per gram of finished product.
A defensible new intact-facial study should begin below the historical wound-gel range: proposed arms 0.01%, 0.05%, and 0.10% w/w at 0.50 g once daily × 24 weeks after formulation, penetration, and tox gates. Raw powder should not be applied neat.
GHK-Cu topical powder in 30 seconds
| Question | Evidence summary |
|---|---|
| Identity | GHK-Cu · Copper Tripeptide-1 · powder = ingredient, not dose |
| ≠ | GHK Basic · prezatide · injectable vial · trade blend without assay |
| Wound RCT | 2% · 4% gel · once daily · area-metered |
| Ongoing trial | 0.1% gel · NCT07437586 · 14 days |
| Cosmetic dose established? | No — dose transparency limited |
| Market convention | ~0.05%–1% (label basis often unclear) |
| Powder math | Powder mg = target active ÷ active fraction |
| Proposed facial study | 0.01% · 0.05% · 0.10% · 0.50 g/day × 24 wk |
What is GHK-Cu topical powder?
GHK-Cu is glycyl-L-histidyl-L-lysine complexed with copper(II) — INCI Copper Tripeptide-1. “Topical powder” describes physical form and intended route, not a standardized drug product.
Two blue powders under the same name can differ in stoichiometry, counterion, hydration, active assay, free copper/peptide, carrier (mannitol/maltodextrin), water content, and microbial quality — all change delivered active mass from a given powder weight.
Identity gate
Confirm GHK-Cu powder — not GHK Basic, prezatide, trade blend, or injectable vial
Formulation ingredient — requires assay and finished-product QC
L-glycyl-L-histidyl-L-lysine copper(II) complex. Confirm sequence, copper coordination, active assay basis (as-is vs anhydrous), free copper/peptide, carrier content, and microbial limits before batch math.
GHK, GHK-Cu, and prezatide are not one mass standard
Representative 401.91 g/mol monocopper complex: elemental copper ≈15.81% of complex mass. Prezatide copper acetate (~862.39 g/mol) is not mass-equivalent to 1:1 GHK-Cu.
Copper composition
Theoretical elemental copper from GHK-Cu complex mass (~401.91 g/mol)
79.0 µg Cu
From 0.5 mg GHK-Cu complex at 15.81% copper fraction — composition only, not absorption.
Mass entities (why assay basis matters)
| Name | Approx. MW | Notes |
|---|---|---|
| GHK (copper-free) | 340.38 g/mol | ≠ GHK-Cu |
| Monocopper GHK-Cu | ~401.91 g/mol | Common 1:1 complex basis |
| Prezatide copper acetate | 862.39 g/mol | Bis-complex entity |
| Trade blend | Product-specific | 1 g ingredient ≠ 1 g active |
What a powder certificate must establish
Generic “99% HPLC purity” does not prove 99% correctly complexed GHK-Cu. Require identity, complex identity, quantitative active assay (with basis), copper-to-peptide ratio, free copper/GHK, related substances, water, solvents, elemental impurities, and microbial limits.
Regulatory and research status
Copper Tripeptide-1 appears in cosmetics — not a therapeutic wound-healing authorization. FDA May 2026: GHK-Cu except injectable in 503A Category 1 (interim compounding evaluation) — does not establish efficacy or standard dose.
This page treats cosmetic use as formulation convention, published studies as indication-specific, registered trials as ongoing research, and proposed protocols as investigator designs requiring full review.
Dosage used in human topical research
Mulder 1994: 181 adults · diabetic ulcers · 0%, 2%, 4% GHK-Cu in HPMC gel · once daily · 2 mg/cm² (2%) or 6 mg/cm² (4%) · up to 8 weeks. Immediate 2% after debridement improved several plantar-ulcer outcomes; delayed treatment did not show the same advantage.
NCT07437586: 0.1% gel · once daily · 14 days · paired 5-mm punch wounds · ~60 healthy adults. Miller 2006: post-CO₂ laser — no significant objective improvement at 12 weeks despite patient satisfaction signal.
Human topical exposures
2%/4% wound gels · 0.1% ongoing trial · cosmetic dose not established
- FDA-approved GHK-Cu drug dose
- None identified
- Mulder 1994 wound gels
- 2% and 4% · once daily · 2 or 6 mg/cm² ulcer area
- NCT07437586 (ongoing)
- 0.1% gel · once daily · 14 days · paired punch wounds
- Bishop 1992 venous ulcer cream
- 0.4% — reported negative
- Miller 2006 post-CO₂ laser
- GHK-Cu regimen — null objective endpoints at 12 wk
- Exact cosmetic anti-aging dose
- Not established from adequately reported trials
- Common market language
- ~0.05%–1% (often label-ambiguous)
- Proposed facial dose-ranging
- 0.01% · 0.05% · 0.10% w/w · 0.50 g daily × 24 wk
Human skin penetration evidence
GHK-Cu is hydrophilic — molecular size alone does not predict intact-skin penetration. Hostynek studied 0.68% aqueous copper as GHK-copper complex under infinite-dose ex-vivo conditions. Li 2015: microneedle pretreatment markedly increased transport — does not validate home microneedling with cosmetic serums.
Intact-skin exposure cannot be inferred from container % alone. Wound, post-laser, microneedled, and intact facial skin are different routes in practical safety terms.
Evidence-tiered concentration landscape
Concentration landscape
0.01% proposed facial arms through 4% historical wound gels
| % w/w | mg/g active | Source | Tier |
|---|---|---|---|
| 0.01% | 0.1 mg/g | Proposed intact-skin arm | Proposed |
| 0.05% | 0.5 mg/g | Vendor/formulator convention | Convention |
| 0.1% | 1 mg/g | NCT07437586 · market convention | Registered trial |
| 0.4% | 4 mg/g | Historical venous-stasis cream | Negative study |
| 0.5% | 5 mg/g | Supplier/clinic range | Convention |
| 1% | 10 mg/g | “1% copper peptide” claims | Often ambiguous |
| 2% | 20 mg/g | Mulder 1994 Iamin 2% gel | Wound RCT |
| 4% | 40 mg/g | Mulder 1994 Iamin 4% gel | Wound RCT |
The cosmetic 0.05%–1% range is assembled from ingredient directories, supplier guides, product labels, and clinic pages — not one coherent clinical protocol.
Clinical versus market protocols
Evidence split
Published/registered research vs market and DIY conventions
Published / registered human research
Indication- and formulation-specific
- Concentrations
- 0.1% (ongoing) · 0.4% (negative) · 2% · 4% wound gels
- Application
- Metered by wound area (Mulder) or 0.50 g pump (proposed facial)
- Frequency
- Once daily in well-described protocols
- Barrier
- Open wound or procedure-altered skin in key studies
- Evidence value
- Exact gel, timing, and care system — not a universal %
Market and DIY practice
Conventions · ambiguous label basis
- Concentrations
- Commonly 0.05%–1%; sometimes 2%–3%
- Application
- “Few drops,” one pump, or unspecified
- Powder handling
- Ad hoc dissolution — often no assay correction
- Barrier
- Intact skin; sometimes microneedling stacks
- Evidence value
- Documents practice; does not prove dose-response
Powder-to-finished-product concentration math
w/w: Target active (mg) = (% ÷ 100) × batch mass (g) × 1000. Powder required (mg) = target active ÷ active fraction. Calculate to final batch mass, not initial liquid volume alone.
w/v: mg/mL = 10 × % w/v. For water-like products, w/w and w/v may appear close but are not interchangeable without density and specification basis.
Batch math (w/w)
Target % × batch mass → required active mass
Target strength
Final batch mass (g)
Target GHK-Cu active mass
100.00 mg
1.000 mg active per gram · 0.1% w/w in 100 g batch
Divide by powder active fraction in the assay calculator — HPLC area purity ≠ active assay.
Assay correction
A 95% assay powder requires 105.3 mg to deliver 100 mg active. A 10% carrier blend requires 1,000 mg for 100 mg active. HPLC area purity should not substitute for active assay without mass balance.
Assay correction
Powder mass = target active ÷ active fraction
Powder specification
Target active (mg)
Powder required
105.26 mg
Delivers 100 mg active · 5.26 mg non-active mass at 95.0% fraction
Powder required for 100 mg assayed active
| Specification | Active fraction | Powder required |
|---|---|---|
| 100% theoretical | 1.000 | 100.0 mg |
| 99% assay | 0.990 | 101.0 mg |
| 95% assay | 0.950 | 105.3 mg |
| 92% assay (worked example) | 0.920 | 108.7 mg |
| 10% blend | 0.100 | 1,000 mg |
| 1% supplier solution | 0.010 | 10,000 mg |
Nested percentages and trade ingredients
If a serum contains 1% of a trade ingredient that is itself 1% GHK-Cu active, finished product active = 1% × 1% = 0.01% (0.1 mg/g) — not 10 mg/g.
Nested percentage
Trade ingredient % × inner active % → finished active concentration
Finished product contains (%)
…of trade ingredient that is active (%)
Effective GHK-Cu active in finished product
0.0100% w/w
= 0.1000 mg active per gram (1% × 1%)
Applied topical dose math
Applied active (mg) = product mass (g) × active concentration (mg/g). Concentration alone is not a dose without application mass.
Applied dose
Product mass × concentration → placed-on-skin active mass
Finished strength
Application mass
GHK-Cu placed on skin
0.500 mg
Theoretical copper (15.81%)
79.0 µg
Placed-on-skin mass — not absorbed fraction. Protocol uses 0.50 g at 0.01% / 0.05% / 0.10% w/w.
Why published wound doses should not become cosmetic recipes
Historical 2%/4% Iamin gel targeted debrided ulcers under sterile unit-dose wound care — not preserved facial cosmetics on intact skin. Transfer ignores barrier differences, HPMC vehicle, area metering, and absence of cosmetic dose-response data.
Higher concentration can increase irritation, staining, instability, and free-copper burden without improving dermal delivery.
Complete investigator-ready research protocol
24-week randomized, double-blind, vehicle-controlled, parallel-group dose-ranging study in mild-to-moderate facial photoaging. Primary: lateral-canthal wrinkle severity at week 24. Arms: vehicle, 0.01%, 0.05%, 0.10% w/w — 0.50 g once daily evening application. 0.1% upper arm aligns with NCT07437586 while avoiding unsupported 2%–4% wound transfer.
Proposed protocol
24-week facial dose-ranging · 0.50 g once daily · GMP finished product
| Arm | Concentration | Daily active | Theoretical Cu |
|---|---|---|---|
| A | Vehicle | 0 mg / 0.50 g | 0 µg |
| B | 0.01% w/w | 0.05 mg / 0.50 g | 7.9 µg |
| C | 0.05% w/w | 0.25 mg / 0.50 g | 39.5 µg |
| D | 0.10% w/w | 0.5 mg / 0.50 g | 79.1 µg |
Enabling requirements · Before enrollment
Identity, assay, formulation, microbiology, stability, permeation, dermal safety, ethics/regulatory
Washout / run-in · Week −4 to 0
Standardized cleanser, moisturizer, SPF; discontinue retinoids and copper products
Sentinel phase · First 24 participants
6 per arm · 7- and 28-day safety review before full enrollment
Treatment · 24 weeks
0.50 g once daily evening · face · no microneedling/injection
Off-treatment follow-up · Week 28
Persistence and delayed safety after final application
Requires GMP finished product — participants do not handle powder. Enabling gates: identity, assay, formulation, microbiology, stability, permeation, dermal safety, ethics/regulatory approval.
Formulation controls for a topical powder study
Screen pH for speciation and stability. Test excipient compatibility (chelators, reducing agents, acids, botanicals). Aqueous products require validated preservation — refrigerator ≠ preservation system. Blue color does not quantify uniformity; gravimetric mixing and content uniformity testing are required.
Safety and adverse effects
Safety monitoring
Local irritation · copper burden · powder handling · barrier disruption
- Local topical
- Stinging, erythema, pruritus, dermatitis, blue-green discoloration — limited formal AE rates for assayed cosmetic use
- Copper-related
- Degradation or free copper increases labile copper burden; Wilson disease is a special concern
- Powder handling
- Airborne dust, eye/mucosal exposure — occupational controls required in manufacturing
- Barrier disruption
- Microneedling, laser, and open wounds change delivery — product for intact skin ≠ channel/wound use
Mechanism of action
GHK-Cu may influence ECM turnover, fibroblast signaling, collagen/GAG production, inflammatory and oxidative pathways, and angiogenesis. Mechanism does not determine human topical concentration, prove penetration, or guarantee visible anti-aging effect.
Common claims vs evidence
Claim checker
Common GHK-Cu topical powder claims vs the evidence record
1% GHK-Cu is the clinically proven facial dose
False
1% is a common marketing convention. Labels often mean 1% trade ingredient, 1% supplier solution, or 1% complex — not 10 mg pure active per gram.
Dosage evidence ladder
Dosage evidence ladder
Wound gels documented — cosmetic powder dose not established
| Level | What exists | Confidence |
|---|---|---|
| FDA-approved topical dose | None | None |
| Controlled wound study | 2% · 4% gels · Mulder 1994 | Moderate · ulcer-specific |
| Ongoing registered trial | 0.1% gel · NCT07437586 | Protocol only |
| Controlled post-procedure | CO₂ laser — null objective result | Negative signal |
| Cosmetic human studies | Small trials · limited dose transparency | Low–moderate |
| Ex-vivo penetration | Hostynek · Li microneedle | Mechanistic |
| Market / DIY protocols | ~0.05%–1% · ambiguous basis | Very low |
Bottom line
GHK-Cu topical powder is not a dose by itself. The usable research dose combines verified identity, assayed active fraction, finished concentration, application mass, frequency, duration, vehicle, and barrier status.
Human evidence spans 0.1% ongoing acute-wound study, historical 2%/4% wound gels, incompletely reported cosmetic studies, and a null post-laser trial. For intact facial skin, the defensible next step is a manufactured vehicle-controlled dose-ranging study — not unsupervised powder-to-serum conversion.
Assay-correct powder math ≠ clinical authorization. 2% wound gel ≠ 2% face serum. 1% label ≠ 1% pure active without quantitative disclosure.
Frequently asked questions
What concentration is clinically proven for facial anti-aging?
No single concentration is established by adequately reported, replicated independent facial trials. The strongest exact-dose evidence comes from wound gels, not routine intact-skin cosmetic use.
Is 1% GHK-Cu the standard topical dose?
It is a common marketing convention, not a universal clinical standard. The label must state whether 1% refers to pure active, a supplier solution, or a multi-ingredient complex.
How much powder makes a 0.1% product?
On a pure-active basis, 0.1% w/w equals 1 mg active per gram, or 100 mg active in a 100 g batch. Actual powder mass must be corrected for assay and carrier content.
Is 0.1% the same as 1 mg/mL?
For 0.1% w/v: yes (1 mg/mL). For 0.1% w/w: equals 1 mg/g. They are numerically close only when density is near 1 g/mL and the specification basis is defined.
Does 99% HPLC purity mean 99 mg active per 100 mg powder?
Not necessarily. HPLC area purity and quantitative active assay are different measurements.
Is GHK-Cu topical powder the same as GHK Basic?
No. GHK Basic is copper-free Gly-His-Lys. GHK-Cu contains coordinated copper with different mass, color, and formulation behavior.
Can injectable GHK-Cu powder be turned into a serum?
An injectable vial label does not establish cosmetic suitability, preservation, pH, stability, or skin compatibility. Route-specific product development is still required.
Can topical powder be dissolved only in water?
Solubility is only one requirement. An aqueous human-use product also needs pH control, compatible excipients, microbial protection, uniformity, and stability data.
Should GHK-Cu be applied once or twice daily?
Well-described wound studies use once-daily dosing. Twice-daily cosmetic schedules circulate without robust comparative trial support.
Can GHK-Cu be used after microneedling?
Microneedles substantially change penetration. A product designed for intact skin should not be assumed suitable for intradermal exposure through fresh channels.
References
Mulder GD et al.
Enhanced healing of ulcers in patients with diabetes by topical GHK-Cu2% and 4% gels · once daily · area-metered dosing.
ClinicalTrials.gov
NCT07437586 — Topical GHK-Cu gel for acute wound healing0.1% gel · 14 days · paired punch wounds.
Miller TR et al.
Copper tripeptide complex on CO2 laser-resurfaced skinNull objective endpoints at 12 weeks.
Hostynek JJ et al.
Human skin penetration of a copper tripeptide in vitroEx-vivo retention/penetration — not cosmetic efficacy.
FDA
Bulk Drug Substances — 503A Category 1 (May 2026)GHK-Cu except injectable — interim compounding classification.
European Commission CosIng
Copper Tripeptide-1 ingredient recordCosmetic ingredient identity reference.